BioCryst Q3 2016 Financial Results and APeX-1 Trial Update

BioCryst presented third quarter 2016 financial results and progress on the APeX-1 Phase 2 clinical trial of BCX7353 for hereditary angioedema (HAE). The double-blind, placebo-controlled trial features a proof-of-concept stage and dose-ranging component evaluating reduction in HAE attacks.